CERRI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.157
EU - Europa 13.115
AS - Asia 9.382
SA - Sud America 1.368
Continente sconosciuto - Info sul continente non disponibili 391
AF - Africa 222
OC - Oceania 30
Totale 46.665
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.480
IT - Italia 6.559
SG - Singapore 3.014
GB - Regno Unito 2.427
CN - Cina 2.196
BR - Brasile 1.028
HK - Hong Kong 1.024
VN - Vietnam 972
SE - Svezia 777
DE - Germania 706
BD - Bangladesh 584
FR - Francia 516
RU - Federazione Russa 452
FI - Finlandia 381
UA - Ucraina 315
CA - Canada 293
NL - Olanda 263
TR - Turchia 254
KR - Corea 253
IN - India 231
ID - Indonesia 194
JP - Giappone 142
MX - Messico 131
BG - Bulgaria 130
AR - Argentina 106
IE - Irlanda 98
IQ - Iraq 76
ES - Italia 72
PL - Polonia 69
PK - Pakistan 62
ZA - Sudafrica 58
IL - Israele 56
CR - Costa Rica 51
EC - Ecuador 51
BE - Belgio 50
CO - Colombia 44
VE - Venezuela 40
AT - Austria 35
RO - Romania 35
AE - Emirati Arabi Uniti 34
CL - Cile 33
LT - Lituania 32
MY - Malesia 29
MA - Marocco 28
CH - Svizzera 27
HN - Honduras 27
SA - Arabia Saudita 27
SC - Seychelles 26
EG - Egitto 24
TW - Taiwan 24
JM - Giamaica 23
JO - Giordania 23
PE - Perù 23
AU - Australia 21
NI - Nicaragua 21
GT - Guatemala 20
TN - Tunisia 20
KE - Kenya 19
PH - Filippine 19
SV - El Salvador 19
CW - ???statistics.table.value.countryCode.CW??? 18
DZ - Algeria 18
IR - Iran 18
PY - Paraguay 18
TT - Trinidad e Tobago 18
UZ - Uzbekistan 18
AZ - Azerbaigian 17
CZ - Repubblica Ceca 17
GP - Guadalupe 17
NP - Nepal 16
PR - Porto Rico 16
TH - Thailandia 16
DK - Danimarca 15
RS - Serbia 14
UY - Uruguay 14
AL - Albania 13
DO - Repubblica Dominicana 13
EE - Estonia 13
LV - Lettonia 13
HR - Croazia 12
HU - Ungheria 12
PT - Portogallo 10
NZ - Nuova Zelanda 9
BB - Barbados 8
BO - Bolivia 8
EU - Europa 8
GE - Georgia 8
SN - Senegal 8
BH - Bahrain 7
KG - Kirghizistan 7
KZ - Kazakistan 7
NO - Norvegia 7
SI - Slovenia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
OM - Oman 6
BY - Bielorussia 5
ET - Etiopia 5
KW - Kuwait 5
LB - Libano 5
Totale 46.203
Salva come PNG Salva come JPEG
Città #
Ashburn 2.742
Singapore 2.029
Santa Clara 1.806
Fairfield 1.689
Southend 1.635
San Jose 1.359
Hong Kong 992
Woodbridge 992
Chandler 947
Council Bluffs 852
Houston 761
Seattle 625
Wilmington 547
Milan 518
Cambridge 516
Hefei 514
Beijing 490
Dearborn 469
Ann Arbor 444
Nyköping 444
Jacksonville 432
Rome 418
New York 370
London 369
Los Angeles 301
Ho Chi Minh City 269
Helsinki 261
The Dalles 261
Modena 253
Hanoi 246
Seoul 208
Chicago 199
San Diego 185
Naples 158
Dallas 155
Bologna 152
Jakarta 145
Princeton 127
Sofia 124
Buffalo 122
Florence 119
Lauterbourg 117
Columbus 113
São Paulo 107
Palermo 106
Tokyo 106
Eugene 105
Shanghai 99
Munich 95
Izmir 93
Moscow 93
Phoenix 89
Bari 85
Orem 85
Redwood City 84
Salt Lake City 83
Boardman 75
Toronto 73
Catania 70
Dublin 68
Turin 68
Atlanta 66
Frankfurt am Main 65
Reggio Emilia 59
Montreal 58
Bremen 56
Brooklyn 50
Mexico City 50
North Bergen 48
San Francisco 48
Genoa 47
Verona 47
Da Nang 46
Guangzhou 41
Warsaw 41
Brussels 40
Charlotte 40
Chennai 38
Denver 38
Cagliari 37
Elk Grove Village 37
Dong Ket 36
Padova 35
Parma 35
San José 35
Haiphong 34
Nuremberg 34
Poplar 32
Rio de Janeiro 32
Tampa 32
Miano 30
Boston 29
Turku 29
Baghdad 28
Brescia 28
Manchester 28
Philadelphia 28
Redondo Beach 28
Falls Church 27
Lahore 27
Totale 28.598
Salva come PNG Salva come JPEG
Nome #
INTERSTIZIOPATIA POLMONARE NON CLASSIFICABILE O SECONDARIA A CONNETTIVITE INDIFFERENZIATA. IMPORTANZA E DIFFICOLTÀ DI UNA DIAGNOSI DIFFERENZIALE. 3.908
Malattie infiltrative diffuse del polmone 1.275
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 830
Non-steroid agents for idiopathic pulmonary fibrosis 535
Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease 507
Acute exacerbation of Idiopathic Pulmonary Fibrosis: lessons learned from the Acute Respiratory Distress Syndrome 458
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 452
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 447
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 434
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 432
Effectiveness of pulmonary rehabilitation in patients with INTERSTITIAL LUNG DISEASE of different etiology: a multicenter prospective study 400
Proteomics Analysis of Formalin-Fixed Paraffine-Embedded Tissue Reveals Key Proteins Related to Lung Dysfunction in Idiopathic Pulmonary Fibrosis. 395
Morbidity and Mortality in Patients with Idiopathic Pulmonary Fibrosis Undergoing Diagnostic Surgical Lung Biopsy 386
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 383
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 382
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 381
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 379
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 375
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 370
NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES 368
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 362
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 355
Emerging drugs for idiopathic pulmonary fibrosis. 353
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 353
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 348
Serial Ultrasound Assessment of Diaphragmatic Function and Clinical Outcome in Patients with Amyotrophic Lateral Sclerosis. 347
Pulmonary stretch and lung mechanotransduction: Implications for progression in the fibrotic lung 347
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 345
Expression of HOXB7 in the lung of patients with idiopathic pulmonary fibrosis: a proof of concept study. 344
Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. 344
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 342
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 341
Management of idiopathic pulmonary fibrosis. 338
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 337
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. 332
Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. 332
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 330
Rifabutin for treating pulmonary tuberculosis. 328
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 327
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 325
Inspiratory effort and respiratory mechanics in spontaneously breathing patients with acute exacerbation of idiopathic pulmonary fibrosis: a retrospective matched control study. 325
Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases 324
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 323
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 320
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 320
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 317
Sarcoidosis: challenging diagnostic aspects of an old disease. 316
Pulmonary fibrosis and the many faces of UIP 316
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 313
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature 312
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 310
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 310
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 308
Management of Idiopathic Pulmonary Fibrosis 308
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 307
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis. 307
AB1157 VALIDATION OF VECTOR (VELCRO CRACKLES DETECTOR) FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES 303
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 297
Ultrasound assessed Diaphragm Impairment is a Predictor of Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease undergoing Non-Invasive Ventilation. 296
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 294
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 294
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 290
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 288
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 288
Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment. 286
Copd, pulmonary fibrosis and ilas in aging smokers: The paradox of striking different responses to the major risk factors 280
Smoking-related interstitial lung disease 279
Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? 278
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 277
The encaged lung: rapidly progressive idiopathic pleurisy. 277
Empoyment of the ELISPOT blood test for the diagnosis of latent tuberculosis infection in dialysis patients awaiting renal transplantation 277
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review 276
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 275
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 274
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 273
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 272
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease 272
The big clinical trials in idiopathic pulmonary fibrosis. 271
Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis 269
Challenges in idiopathic interstitial lung disease 267
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 266
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 266
Biological effects of COVID-19 on lung cancer: can we drive our decisions? 263
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 262
Predicting Mortality in Patients with Rheumatoid Arthritis Related Interstitial Lung Disease: Expanding The GAP Model 258
Impact of Mesenchymal Stromal/stem Cell Infusions on Circulating Inflammatory Biomarkers in COVID-19 Patients: Analysis of a Phase I-IIa Trial. 257
AB0472 PRIMARY SJOGREN SYNDROME ASSOCIATED INTERSTITIAL LUNG DISEASE: FEATURES, TREATMENT AND OUTCOME OF A MONOCENTRIC COHORT 255
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 254
Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? 254
Janus-faced amiodarone-induced pneumopathy 249
Human mucosal associated invariant T cells detect bacterially infected cells 247
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases. 245
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 243
Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients 240
Physiological effects of lung protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study. 239
Tubercolosi 238
The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance. 232
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 232
Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis 230
CHARACTERIZATION OF ANTI-MPO POSITIVE INTERSTITIAL LUNG DISEASE. CLINICAL-SEROLOGIC AND RADIOLOGIC FEATURES AND SURVIVAL 227
Totale 36.673
Salva come PNG Salva come JPEG
Categoria #
all - tutte 161.325
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 161.325
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.059 0 0 0 0 142 187 146 156 332 226 495 375
2022/20233.613 349 340 237 313 360 424 166 381 428 144 260 211
2023/20243.644 172 201 235 342 471 373 470 407 127 145 305 396
2024/20257.344 315 177 220 503 1.353 982 670 458 755 337 667 907
2025/202613.480 870 496 975 1.429 1.881 905 1.649 717 1.299 1.206 1.175 878
2026/20274.914 496 1.054 1.201 1.769 394 0 0 0 0 0 0 0
Totale 46.665